DescriptionCardiol Therapeutics Inc is a clinical-stage life sciences company developing therapies for cardiovascular disease (CVD). The lead product, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation being investigated in a Phase II/III study in hospitalized patients testing positive for COVID-19 with a prior history of, or risk factors for, CVD. The CardiolRx is also being investigated in patients with acute myocarditis, a leading cause of cardiac death in people less than 35 years old.
Corporate earnings are provided from Morningstar, including Income Statements,Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.
Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research.
A premium report that provides detailed quantitative assessments of earnings, fundamentals, relative valuation, risk, price momentum and more. For subscribers only.
What is this stock worth in intrinsic value? View this premium StockCalc report to see this stock's valuation and how it was calculated using fundamental analysis. For subscribers only.
Latest Press Releases
|Period||Period Low||Period High||Performance|
|1-Month|| 1.97 +47.21% increase |
| 2.95 -1.69% decrease |
| +0.31 (+11.97%) increase |
|3-Month|| 1.97 +47.21% increase |
| 6.11 -52.54% decrease |
| -2.46 (-45.90%) decrease |
|52-Week|| 1.97 +47.21% increase |
| 6.19 -53.15% decrease |
| -0.37 (-11.31%) decrease |